Particle.news
Get it on Google Play
Download on the App Store

Health ❯ Healthcare ❯ Pharmacology

Immunotherapy

Pembrolizumab Nivolumab Tislelizumab Avelumab Nivolumab and Ipilimumab Bispecific T-cell Engagers Cemiplimab OX40 Inhibitors PD-L1 Inhibitors Chemo-immunotherapy Durvalumab

Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar